Hutchison China Meditech Ltd (HCM)

12.00
NASDAQ : Health Care
Prev Close 12.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 9.80 / 14.70
Avg Volume 31.20K
Exchange NASDAQ
Shares Outstanding 120.57M
Market Cap 1.46B
EPS -0.30
Div & Yield N.A. (N.A)

Latest News

Chi-Med And AstraZeneca Amend Co-development Agreement To Accelerate Savolitinib Global Development Program

Chi-Med And AstraZeneca Amend Co-development Agreement To Accelerate Savolitinib Global Development Program

Chi-Med and AstraZeneca today announced an amendment (the "Amendment") to the 2011 global licensing, co-development, and commercialisation agreement (the "2011 Agreement") regarding savolitinib.

Chi-Med Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib In Colorectal Cancer

Chi-Med Completes Enrollment Of 416 Patients In Pivotal Phase III FRESCO Trial With Fruquintinib In Colorectal Cancer

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq:HCM) today announces that it has completed patient enrollment of FRESCO, its Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced or...

Chi-Med To Participate In Two Healthcare Investor Conferences In May

Chi-Med To Participate In Two Healthcare Investor Conferences In May

Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May.

Hutchison China MediTech Limited Announces Exercise Of Overallotment Option

Hutchison China MediTech Limited Announces Exercise Of Overallotment Option

Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares ("ADSs") on the Nasdaq Global Select Market (the "Offering") have exercised their...

Chi-Med Initiates First-in-Human Clinical Trial Of Novel PI3K Inhibitor HMPL-689

Chi-Med Initiates First-in-Human Clinical Trial Of Novel PI3K Inhibitor HMPL-689

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the first-in-human ("FIH") Phase I clinical trial of...

Hutchison China MediTech Limited Announces Closing Of U.S. Public Offering Of ADSs Raising Approximately US$101 Million On The Nasdaq Stock Market

Hutchison China MediTech Limited Announces Closing Of U.S. Public Offering Of ADSs Raising Approximately US$101 Million On The Nasdaq Stock Market

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces the closing of its U.

Chi-Med Initiates Sulfatinib Phase III Registration Study In Pancreatic Neuroendocrine Tumor Patients

Chi-Med Initiates Sulfatinib Phase III Registration Study In Pancreatic Neuroendocrine Tumor Patients

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of sulfatinib...

Hutchison China MediTech Limited Announces Pricing Of U.S. Public Offering Of ADSs

Hutchison China MediTech Limited Announces Pricing Of U.S. Public Offering Of ADSs

Hutchison China MediTech Limited ("Chi-Med") (AIM:HCM) announces the pricing of its U.

Hanover Capital Delays Filing

The company cites conditions in the mortgage market.